Keywords: cydex, presents, strong, data, nasal, sprays, kansas
CyDex presents strong data for nasal sprays
Article | 23 March 2009
Kansas, USA-based CyDex Pharmaceuticals presented Phase II trial results for its Captisol-Enabled budesonide/azelastine nasal spray for seasonal allergic rhinitis, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
